•  
  •  
  •  
  •  

2025-10-02 02:05:35

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Hero MotoCorp Ltd dispatches 687,220 units in September 2025
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Veefin has successfully integrated CRIF's Strategy One BRE with our no-code Digital Lending Stack
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Unimech Aerospace and Manufacturing Ltd experiences slowdown in revenue

Keywords Selected:  Biologics

Stock Report

  • Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
  • CuraTeQ Biologics Pvt Ltd completes Phase 3 Clinical Study for Denosumab Biosimilar
  • U.S. FDA Completes Inspection at Biocon Biologics' Facility at Biocon Campus, Bengaluru, India
  • CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA
  • Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™
  • Biocon Biologics receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars
  • Biocon Biologics expands Insulin Access in Malaysia
  • Biocon Biologics receives Health Canada approval for Yesafili™
  • Biocon Biologics Collaborates with National Cancer Society Malaysia
  • Zydus enters global biologics CDMO business, plans to acquire Agenus’ U.S. manufacturing facilities to accelerate development of innovative therapies
  • Biocon Biologics and Yoshindo expand access to Ustekinumab Biosimilar in Japan
  • Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives
  • Europe (AGES, Austria) Inspection of Shilpa Biologicals Pvt Ltd
  • Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe
  • CuraTeQ Biologics receives positive opinion for biosimilar Dazublys® from EMA
  • Biocon Biologics secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
  • Biocon Biologics announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
  • CuraTeQ Biologics received Marketing Authorization for Dyrupeg™, a pegylated filgrastim biosimilar
  • Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc.
  • Biocon Biologics and Civica, Inc. collaborate to expand Insulin Aspart access in the United States
  • Biocon Biologics Launches Yesintekâ„¢ Biosimilar to Stelara® in the United States
  • European Commission approves Biocon Biologics' Ustekinumab Biosimilar
  • EMA's CHMP recommends approval of Biocon Biologics' YESINTEK®, biosimilar to J&J's Stelara®
  • CuraTeQ Biologics receives positive opinion for biosimilar Zefylti

Latest Post

  • Hero MotoCorp Ltd dispatches 687,220 units in September 2025
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Veefin has successfully integrated CRIF's Strategy One BRE with our no-code Digital Lending Stack
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Unimech Aerospace and Manufacturing Ltd experiences slowdown in revenue


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024